Castle Creek Pharmaceutical completed the acquisition of Fibrocell Science for $63m.

Castle Creek Pharmaceutical, a privately-held biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions, completed the acquisition of Fibrocell Science, a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, for $63m. With the resources of CCP, Fibrocell's gene therapy platform can be advanced into additional areas of high, unmet need with the potential to develop multiple, promising new therapies. "Fibrocell's unique and innovative gene therapy platform provides us with development opportunities that will strengthen the combined company as a leader for EB and other rare conditions where there are limited options for affected patients," Mary Spellman, Castle Creek's Chief Medical Officer and Senior Vice President of Research & Development.